Skip to main content

Table 1 Summarised cohort/stratified baseline characteristics of patients receiving biologic drugs, analysed for CD11c expression by qPCR

From: Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples

  Full cohort (n = 75) Etanercept (n = 50) Adalimumab (n = 25)
Cohort characteristics NR (n = 34) R (n = 41) P value NR (n = 25) R (n = 25) P value NR (n = 9) R (n = 16) P value
Gender, female, n (%) 27 (79.4 %) 31 (75.6 %) 0.695a 20 (80 %) 20 (80 %) 1.00a 7 (77.8 %) 11 (68.8 %) 0.629a
Age, baseline, years, mean (SD) 59.3 (12.3) 53.3 (10.3) 0.023b 61.2 (12.2) 54.86 (11.4) 0.065b 54.3 (11.7) 50.7 (8.2) 0.258b
Concurrent DMARDs, n (%) 28 (82.4 %) 36 (90 %) 0.338a 22 (88 %) 21 (84 %) 0.684a 6 (66.7 %) 15 (100 %) 0.017a
Baseline DAS28, median (IQR) 6.2 (5.4–6.6) 5.8 (5.5–6.3) 0.131c 6.2 (5.8–6.6) 5.9 (5.5–6.2) 0.156c 6.6 (5.6–7.03) 5.6 (5.3–6) 0.101c
3 month DAS28, median (IQR) 5.65 (5.4–6.2) 2.15 (1.6–2.5) <0.001c 5.6 (5.3–5.9) 2.3 (1.9–3) <0.001c 6.6 (5.3–6.8) 1.95 (1.6–2.2) <0.001c
Baseline TJC, median (IQR) 16 (10–19) 13 (10–16) 0.205c 14 (10–18) 13 (10–15) 0.515c 18 (16–24) 13 (10–19) 0.157c
Baseline SJC, median (IQR) 8.5 (4–13) 9 (6–13) 0.701c 7 (4–11) 9 (6–13) 0.268c 11 (9–15) 8.5 (6–13) 0.211c
Baseline ESR, median (IQR), n 33 (14–44), 26 18 (14–33), 35 0.11c 32 (23–41), 21 18 (10–34), 23 0.158c 34 (10–60), 5 20.5 (14–31), 12 0.712c
Baseline HAQ, median (IQR), n 2.06 (1.38–2.3), 22 1.5 (1.13–2), 32 0.026c 2.1 (1.9–2.3), 17 1.4 (1.1–1.6), 19 0.006c 1.9 (1.3–2.1), 5 1.8 (1.1–2.4), 13 0.96c
Tempus™ Blood Tube, n (%) 21 (61.8 %) 22 (53.4 %) 0.48a 15 (60 %) 14 (56 %) 0.774a 6 (66.67 %) 8 (50 %) 0.420a
  1. aCalculated using chi-square test. bCalculated using two independent samples t test. cCalculated using Wilcoxon-Mann–Whitney test. Samples were grouped according to treatment response. NR non-responders, R responders, DAS28 disease activity score in 28 joints, SJC swollen joint count, TJC tender joint count, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us